A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
← catalyst calendarNCT06742996 · readout in 743 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
300estimated
Sites
155
Countries
Argentina, Australia, Austria +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-05 | actual | When the study began enrolling |
| Primary completion | 2028-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mantle Cell Lymphoma
- B Cell Lymphoma
Interventions
- Drug: Sonrotoclax — also filed as BGB-11417
- Drug: Zanubrutinib — also filed as Brukinsa, BGB-3111
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)
measured Approximately 41 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed